IKEMA: Carfilzomib and dexamethasone plus isatuximab for r/r multiple myeloma
Published: 25 Jun 2020
Views: 220
Prof Philippe Moreau - University of Nantes, Nantes, France
Prof Philippe Moreau speaks to ecancer in an online interview for the virtual EHA 2020 meeting.
He discusses the IKEMA trial which looked at carfilzomib and dexamethasone vs carfilzomib and dexamethasone plus isatuximab in relapsed/refractory multiple myeloma.
Related Videos
Phase II data from the KarMMa trial for relapsed/refractory multiple myeloma
Dr Nikhil Munshi - Dana Farber Cancer Institute, Boston, USA
16 Jun 2020
OPTIC: A dose-ranging study of 3 starting doses of ponatinib for chronic-phase c...
Prof Jorge Cortes - Augusta University, Augusta, USA
13 Jun 2020
Investigating KRd versus KTd in NDMM patients with high-risk cytogenetics
Prof Heinz Ludwig - Wilhelmeninen Cancer Research Institute, Vienna, Austria
13 Jun 2020
CANDOR trial design: Investigating KdD versus Kd in relapsed/refractory multiple...
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
13 Jun 2020
Teclistamab for patients with heavily pretreated relapsed or refractory multiple...
Dr Saad Usmani - Levine Cancer Institute, Charlotte, USA
1 Jun 2020
Improved outcomes from quadruplet KCRD induction in newly diagnosed myeloma pati...
Dr Charlotte Pawlyn - Royal Marsden Hospital, London, UK
25 Sep 2019
First results of the GMMG-CONCEPT trial for multiple myeloma
Prof Katja Weisel - University Medical Center Hamburg-Eppendorf, Hamburg, German...
25 Sep 2019
Ruxolitinib, lenalidomide and methylprednisolone for relapsed/refractory multipl...
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
25 Sep 2019
Treatment options for high risk relapsed/refractory multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
25 Sep 2019
